Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
(Adds shares in paragraph 6, investor comment in paragraph 7) By Maggie Fick LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Novo Nordisk (NVO) stock was trading down Thursday despite strong first quarter results, beating Wall Street consensus, led by the blockbuster GLP-1s Ozempic for diabetes and Wegovy for weight loss.
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.